Home Newsfeeds Jefferies Maintains Hold on Hartford Finl Servs Gr, Lowers Price Target to $72

Jefferies Maintains Hold on Hartford Finl Servs Gr, Lowers Price Target to $72

Jefferies analyst Yaron Kinar maintains Hartford Finl Servs Gr (NYSE:HIG) with a Hold and lowers the price target from $77 to $72.

byBenzinga Newsdesk

July 12, 2022

1 minute read

Jefferies analyst Yaron Kinar maintains Hartford Finl Servs Gr (NYSE:HIG) with a Hold and lowers the price target from $77 to $72.

News

Worldwide Clinical Trials Enters Into Collaboration With Invitae To Accelerate Clinical Trials For Rare Disease Patients

By Bill Haddad

July 12, 8:20 AM

CRO gains access to genetic testing data, aims to improve global research with enhanced data insights and faster patient recruitment for rare disease studies Worldwide Clinical Trials, Inc. (Worldwide), the

NVTA

‘Eye-Popping For The Fed’: 5 Experts React To November Jobs Report, What It Means For Interest Rates

By Wayne Duggan

December 2, 11:39 AM

The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported strong U.S. jobs market numbers from November.

APTV

Fed’s Bostic Says This May Be The Labor Market Catching Up To Output, But Doesn’t Necessarily Represent Recessionary Issue

By Benzinga Newsdesk

July 8, 8:58 AM

-Reuters

SPY

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting

By Benzinga Newsdesk

April 25, 4:40 PM

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the

ADVM

Jefferies Maintains Hold on Hartford Finl Servs Gr, Lowers Price Target to $72

Related Posts

Worldwide Clinical Trials Enters Into Collaboration With Invitae To Accelerate Clinical Trials For Rare Disease Patients

‘Eye-Popping For The Fed’: 5 Experts React To November Jobs Report, What It Means For Interest Rates

Fed’s Bostic Says This May Be The Labor Market Catching Up To Output, But Doesn’t Necessarily Represent Recessionary Issue

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting